Anticancer agent 139 exhibits potent anticancer activity against SNB-19, OVCAR-8, and NCI-H460 (PGI values of 86.61, 85.26, and 75.99, respectively); it also shows moderate anticancer activity against HOP-62, SNB-75, ACHN, NCI/ADR-RES, 786-O, A549/ATCC, HCT-116, and MDA-MB-231 (PGI values of 67.55, 65.46, 59.09, 59.02, 57.88, 56.88, 56.53, 56.40, and 51.88, respectively).